IP Library Granted Patent US 8,604,209
Granted Patent B2
US 8,604,209 · App. 12/577,089 · Granted Dec 10, 2013

Methods for preparing oxazolidinones and compositions containing them

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,604,209
App. No.
12/577,089
Granted
Dec 10, 2013
Kind
B2
Abstract

Methods of preparing a class of oxazolidinones useful to impede bacterial growth are disclosed.

Claims (101)

1. A method of synthesizing a compound of the structure

wherein

R is H,

R 1 a and R 1 b are independently selected from H and F, provided that at least one of R 1 a and R 1 b is F,

Het is tetrazolyl optionally-substituted with methyl;

comprising treating a compound having the structure

wherein R 2 is selected from the group consisting of optionally substituted benzyl and optionally substituted C 1 -C 6 alkyl, with glycidyl ester in the presence of a strong base or an organolitihium salt under conditions to make

wherein the optionally-substituted benzyl and the optionally-substituted C 1 -C 6 alkyl are independently unsubstituted or substituted with halogen or C 1 -C 4 alkyloxy.

2. The method of claim 1 further comprising

reacting

with POCl 3 , POCl(OBn) 2 , or P(N-iPr 2 )(O-tBu) 2 under conditions form

wherein R′ is PO(OH) 2 .

3. The method of claim 2 further comprising

treating the compound of the structure

where R′ is PO(OH) 2 with a base under conditions to form the compound of the structure

wherein R″ is a pharmaceutically acceptable salt of PO(OH) 2 .

4. The method of claim 1 further comprising before said treating step:

coupling a first intermediate of the structure

wherein X is a leaving group, with a second intermediate of the structure

wherein Y is selected from the group consisting of ZnCl 2 , BF 3 , and BR 3 R 4 , wherein R 3 and R 4 are independently selected from the group consisting of OH and optionally-substituted C 1 -C 6 mono and dihydric alcohols, and wherein R 3 and R 4 together may form a ring,

under conditions to produce the compound of the structure

5. The method of claim 4 further comprising before said coupling step:

a) treating an aryl halide of structure 5a

wherein X 1 is leaving group, with a second strong base and then reacting a resulting anion with ZnCl 2 or a trialkylboric acid ester under conditions to form structure 6

or

b) treating the aryl halide of structure 5a with a palladium catalyst and a diester of diboronic acid under conditions to form structure 6

6. The method of claim 5 ,

wherein the second strong base is n-butyl lithium, or the strong base or organolitihium salt is n-butyl lithium; or

wherein the palladium catalyst is PdCl 2 (dppf) 2 .

7. A method of synthesizing a compound of the structure

wherein:

R 2 is selected from the group consisting of optionally substituted benzyl and optionally substituted C 1 -C 6 alkyl wherein the optionally-substituted benzyl and the optionally-substituted C 1 -C 6 alkyl are independently unsubstituted or substituted with halogen or C 1 -C 4 alkyloxy,

R 1 a and R 1 b are independently selected from H and F, provided that at least one of R 1 a and R 1 b is F, and

Het is tetrazolyl optionally-substituted with methyl comprising:

coupling a first intermediate of the structure

wherein X is a leaving group, with a second intermediate of the structure

wherein

Y is selected from the group consisting of ZnCl 2 , BF 3 , and BR 3 R 4 , wherein R 3 and R 4 are independently selected from the group consisting of OH and optionally-substituted C 1 -C 6 mono and dihydric alcohols, and wherein R 3 and R 4 together may form a ring

under conditions to produce the compound of the structure

8. A method of making the second intermediate of the structure

wherein

R 2 is selected from the group consisting of optionally substituted benzyl and optionally substituted C 1 -C 6 alkyl,

R 1 a and R 1 b are independently selected from H and F, provided that at least one of R 1 a and R 1 b is F, and

Y is selected from the group consisting of ZnCl 2 , BF 3 , and BR 3 R 4 , wherein R 3 and R 4 are independently selected from the group consisting of OH and optionally-substituted C 1 -C 6 mono and dihydric alcohols, and wherein R 3 and R 4 together may form a ring;

comprising:

a) treating an aryl halide of structure 5a and

wherein X 1 is leaving group, with a strong base and then reacting a resulting anion with ZnCl 2 or a trialkylboric acid ester under conditions to form structure 6

or

b) treating the aryl halide of structure 5a with a palladium catalyst and a diester of diboronic acid under conditions to form structure 6

9. The method of claim 8 ,

wherein the strong base is n-butyl lithium; or

wherein the palladium catalyst is PdCl 2 (dppf) 2 .

10. The method of claim 1

wherein the treating step is performed in the presence of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone.

11. The method of claim 4 , wherein X is selected from the group consisting of Cl, Br, I, and trifluoromethanesulfonate.

12. The method of claim 7 wherein the coupling is carried out in the presence of a palladium complex.

13. The method of claim 12 , wherein the palladium complex is a phosphine ligand bound to palladium.

14. The method of claim 13 , wherein the palladium complex is selected from the group consisting of dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), and Pd 2 (dba) 3 .

15. The method of claim 14 , wherein the palladium complex is Pd 2 (dba) 3 .

16. The method of claim 5 , wherein Y is selected from the group consisting of B(OH) 2 , BF 3 , and

17. The method of claim 16 , wherein Y is B(OH) 2 .

18. The method of claim 1 wherein Het is 2-methyl-tetrazol-5-yl.

19. The method of claim 4 wherein Het is 2-methyl-tetrazol-5-yl and X is Br.

20. The method of claim 3 ,

wherein the base is a sodium base and wherein R″ is PO 3 Na 2 .

21. The method of claim 7 , further comprising treating the compound of the structure

with a glycidyl ester.

22. The method of claim 1 , wherein the glycidyl ester is glycidyl butyrate.

23. The method of claim 1 wherein the glycidyl ester has R stereochemistry.

24. The method of claim 1 , wherein the glycidyl ester is R-(−)-glycidyl butyrate.

25. The method of claim 1 , wherein the treating of the compound of the structure

with a glycidyl ester is carried out in the presence of lithium hexamethyldisilazide.

26. The method of claim 1 , wherein the compound of the structure

is

27. The method of claim 2 , wherein the compound of the structure

28. The method of claim 3 , wherein the compound of the structure

29. The process of claim 1 further comprising

recrystallizing a mixture comprising palladium and

before said treating step to reduce the palladium level.

30. The process of claim 18 further comprising

recrystallizing a mixture comprising palladium and

before said treating step to reduce the palladium level.

31. A method of synthesizing a compound of the structure

wherein

R is H,

R 1 a is F and R 1 b is H, and

Het is 2-methyl-tetrazol-5-yl,

comprising recrystallizing a mixture comprising palladium and

to reduce the palladium level, wherein R 2 is selected from the group consisting of optionally substituted benzyl and optionally substituted C 1 -C 6 alkyl, and

treating the recrystallized compound having the structure

with glycidyl ester in the presence of a strong base or an organolitihium salt under conditions to make

wherein the optionally-substituted benzyl and the optionally-substituted C 1 -C 6 alkyl are independently unsubstituted or substituted with halogen or C 1 -C 4 alkyloxy.

32. The method of claim 31 ,

wherein R 2 is benzyl;

wherein the strong base or the organolitihium salt is n-butyl lithium;

wherein the palladium catalyst is Pd 2 (dba) 3 ; and

wherein the glycidyl ester is R-(−)-glycidyl butyrate.

33. The method of claim 4 , wherein the coupling is carried out in the presence of a palladium complex.

34. The method of claim 33 , wherein the palladium complex complex is a phosphine ligand bound to palladium.

35. The method of claim 34 wherein the palladium complex is selected from the group consisting of dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), and Pd 2 (dba) 3 .

36. The method of claim 35 , wherein the palladium complex is Pd 2 (dba) 3 .

Assignments (8)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 3, 2015
From: TRIUS THERAPEUTICS LLC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036484/0796 →
CHANGE OF NAME Recorded Sep 2, 2015
From: TRIUS THERAPEUTICS, INC.
To: TRIUS THERAPEUTICS LLC
Reel/Frame 036528/0029 →
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: TRIUS THERAPEUTICS, INC.; OPTIMER PHARMACEUTICALS, INC.
Reel/Frame 036178/0175 →
SECURITY AGREEMENT Recorded Nov 13, 2013
From: OPTIMER PHARMACEUTICALS, INC.; TRIUS THERAPEUTICS INC.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 031628/0850 →
RELEASE OF SECURITY INTEREST Recorded Aug 26, 2010
From: SOFINNOVA VENTURE PARTNERS VII, L.P.
To: TRIUS THERAPEUTICS, INC.
Reel/Frame 024895/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2009
From: COSTELLO, CARRIE A.; SIMSON, JACQUELINE A.; DUGUID, ROBERT J.; PHILLIPSON, DOUGLAS
To: TRIUS THERAPEUTICS
Reel/Frame 023644/0247 →
SECURITY AGREEMENT Recorded Nov 10, 2009
From: TRIUS THERAPEUTICS, INC.
To: SOFINNOVA VENTURE PARTNERS VII, L.P., AS COLLATERAL AGENT
Reel/Frame 023496/0079 →